NASDAQ:NKTX Nkarta (NKTX) Stock Price, News & Analysis $5.32 -0.11 (-2.03%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$5.19▼$5.4550-Day Range$4.93▼$8.0052-Week Range$1.28▼$16.24Volume382,149 shsAverage Volume1.26 million shsMarket Capitalization$262.89 millionP/E RatioN/ADividend YieldN/APrice Target$18.20 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Nkarta alerts: Email Address Nkarta MarketRank™ Stock AnalysisAnalyst RatingBuy3.20 Rating ScoreUpside/Downside242.1% Upside$18.20 Price TargetShort InterestBearish15.68% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.00Based on 2 Articles This WeekInsider TradingSelling Shares$27,168 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($1.92) to ($1.98) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.23 out of 5 starsMedical Sector716th out of 910 stocksPharmaceutical Preparations Industry336th out of 426 stocks 3.6 Analyst's Opinion Consensus RatingNkarta has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageNkarta has only been the subject of 3 research reports in the past 90 days.Read more about Nkarta's stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted15.68% of the outstanding shares of Nkarta have been sold short.Short Interest Ratio / Days to CoverNkarta has a short interest ratio ("days to cover") of 10.8, which indicates bearish sentiment.Change versus previous monthShort interest in Nkarta has recently increased by 8.70%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldNkarta does not currently pay a dividend.Dividend GrowthNkarta does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NKTX. Previous Next 1.1 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 2 news articles for Nkarta this week, compared to 2 articles on an average week.Search Interest12 people have searched for NKTX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows4 people have added Nkarta to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Nkarta insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $27,168.00 in company stock.Percentage Held by InsidersOnly 8.70% of the stock of Nkarta is held by insiders.Percentage Held by Institutions80.54% of the stock of Nkarta is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Nkarta's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Nkarta are expected to decrease in the coming year, from ($1.92) to ($1.98) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Nkarta is -2.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Nkarta is -2.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNkarta has a P/B Ratio of 0.83. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Nkarta's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsNASDAQ to crash 50%?During the 2020 Covid Crash he called a market reversal - eleven days before the S&P bottomed out... Now, he's saying there are four major cracks forming in the US economy...Click here to learn more >>> About Nkarta Stock (NASDAQ:NKTX)Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis. It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical trial for the treatment of r/r acute myeloid leukemia or higher risk myelodysplastic syndromes, as well as for solid tumors. In addition, the company develops NKX070, targeting the CD70 tumor antigen to treat solid and liquid tumors; and NK+T cell therapy for use in the treatment of oncology, autoimmune disease, or infectious disease. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.Read More NKTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NKTX Stock News HeadlinesSeptember 7 at 3:15 AM | americanbankingnews.comNkarta (NASDAQ:NKTX) Stock Price Down 2%September 3, 2024 | globenewswire.comNkarta to Participate in Upcoming Investor ConferenceSeptember 7, 2024 | Behind the Markets (Ad)NASDAQ to crash 50%?During the 2020 Covid Crash he called a market reversal - eleven days before the S&P bottomed out... Now, he's saying there are four major cracks forming in the US economy...August 17, 2024 | markets.businessinsider.comBuy Rating Affirmed for Nkarta Amid Strategic Focus and Promising Clinical TrialsAugust 15, 2024 | markets.businessinsider.comBuy Rating on Nkarta Amid Promising Clinical Trials and Solid Financial PositionAugust 15, 2024 | seekingalpha.comNkarta: NK Cell Therapy Biotech With Good Standing Targeting R/R NHL PatientsAugust 14, 2024 | fool.comWhy Nkarta Stock Is Soaring TodayAugust 14, 2024 | msn.comNkarta upgraded at Raymond James on valuationSeptember 7, 2024 | Behind the Markets (Ad)NASDAQ to crash 50%?During the 2020 Covid Crash he called a market reversal - eleven days before the S&P bottomed out... Now, he's saying there are four major cracks forming in the US economy...August 13, 2024 | globenewswire.comCorrection: Nkarta Reports Second Quarter 2024 Financial Results and Corporate HighlightsAugust 13, 2024 | globenewswire.comNkarta Reports Second Quarter 2024 Financial Results and Corporate HighlightsAugust 13, 2024 | msn.comNkarta’s (NKTX) Making Promising Progress in Its Clinical-Stage JourneyJuly 24, 2024 | markets.businessinsider.comBuy Rating Confirmed: Expanding Potential of Nkarta’s NKX019 in SLE TreatmentJuly 24, 2024 | sg.finance.yahoo.comBRIEF-Ley Choon Group Says Units Secured Contracts Worth S$14 MlnJuly 24, 2024 | globenewswire.comNkarta Announces Initiation of Investigator-Sponsored Clinical Trial Evaluating NKX019 for Systemic Lupus ErythematosusJuly 16, 2024 | globenewswire.comNkarta Announces Leadership Updates, Appoints Nadir Mahmood as PresidentJuly 1, 2024 | investorplace.com3 Undervalued Stocks Primed for a 2X ReturnJune 27, 2024 | globenewswire.comNkarta Initiates Clinical Trial of NKX019 in Lupus Nephritis with First Patient in Screening and Announces Pipeline Expansion to Additional Autoimmune IndicationsSee More Headlines Receive NKTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nkarta and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/13/2024Today9/07/2024Next Earnings (Estimated)11/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:NKTX CUSIPN/A CIK1787400 Webwww.nkartatx.com Phone925-407-1049FaxN/AEmployees140Year FoundedN/APrice Target and Rating Average Stock Price Target$18.20 High Stock Price Target$25.00 Low Stock Price Target$13.00 Potential Upside/Downside+242.1%Consensus RatingBuy Rating Score (0-4)3.20 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($2.35) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-117,500,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-28.83% Return on Assets-22.53% Debt Debt-to-Equity RatioN/A Current Ratio15.90 Quick Ratio15.91 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$6.42 per share Price / Book0.83Miscellaneous Outstanding Shares49,416,000Free Float45,117,000Market Cap$262.89 million OptionableOptionable Beta0.81 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. Paul J. Hastings (Age 64)CEO, President & Director Comp: $935.18kMs. Alyssa Levin C.A. (Age 39)CPA, Chief Financial & Business Officer and Principal Accounting Officer Comp: $762.4kDr. David R. Shook M.D. (Age 46)Chief Medical Officer Comp: $631.55kDr. Ralph Brandenberger Ph.D. (Age 55)Chief Technical Officer Dr. James Trager Ph.D. (Age 61)Chief Scientific Officer Mr. Greg MannVice President of Public Affairs and Investor RelationsDr. Alicia J. Hager (Age 54)Chief Legal Officer & Corporate Secretary Comp: $590.94kMore ExecutivesKey CompetitorsFate TherapeuticsNASDAQ:FATENantKwestNASDAQ:NKCelyad OncologyNASDAQ:CYADAvadel PharmaceuticalsNASDAQ:AVDLNewAmsterdam PharmaNASDAQ:NAMSView All CompetitorsInsiders & InstitutionsForefront Analytics LLCBought 11,833 shares on 8/16/2024Ownership: 0.024%Deerfield Management Company L.P. Series CSold 1,394,944 shares on 8/15/2024Ownership: 7.688%Affinity Asset Advisors LLCBought 200,000 shares on 8/15/2024Ownership: 0.405%AQR Capital Management LLCBought 158,736 shares on 8/15/2024Ownership: 0.321%The Manufacturers Life Insurance Company Bought 9,975 shares on 8/15/2024Ownership: 0.042%View All Insider TransactionsView All Institutional Transactions NKTX Stock Analysis - Frequently Asked Questions How have NKTX shares performed this year? Nkarta's stock was trading at $6.60 on January 1st, 2024. Since then, NKTX stock has decreased by 19.4% and is now trading at $5.32. View the best growth stocks for 2024 here. How were Nkarta's earnings last quarter? Nkarta, Inc. (NASDAQ:NKTX) announced its quarterly earnings data on Tuesday, August, 13th. The company reported ($0.34) EPS for the quarter, beating analysts' consensus estimates of ($0.49) by $0.15. When did Nkarta IPO? Nkarta (NKTX) raised $150 million in an initial public offering (IPO) on Friday, July 10th 2020. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. Cowen, Evercore ISI, Stifel and Mizuho Securities served as the underwriters for the IPO. Who are Nkarta's major shareholders? Top institutional investors of Nkarta include Deerfield Management Company L.P. Series C (7.69%), Renaissance Technologies LLC (1.85%), Marshall Wace LLP (0.89%) and Acadian Asset Management LLC (0.61%). Insiders that own company stock include Ra Capital Management, LP, Simeon George, Paul J Hastings, James Trager, David Shook, Alicia J Hager and Ralph Brandenberger. View institutional ownership trends. How do I buy shares of Nkarta? Shares of NKTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Nkarta own? Based on aggregate information from My MarketBeat watchlists, some other companies that Nkarta investors own include Axcella Health (AXLA), Cronos Group (CRON), Block (SQ), Advanced Micro Devices (AMD), ASML (ASML), Beyond Meat (BYND) and Citigroup (C). This page (NASDAQ:NKTX) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nkarta, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nkarta With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
